



# BIKTARVY<sup>®</sup>

bictegravir 50mg/emtricitabine 200mg/  
tenofovir alafenamide 25mg tablets

You Are Invited to Attend...

96-Week Data Update

## BIKTARVY<sup>®</sup>: Efficacy and Safety in Five Phase 3 Clinical Trials

Jeffrey Stephens, MD, FACP, FIDSA

Thursday, March 21, 2019  
6:00 PM

Hunters Pub  
11269 GA Highway 219  
Hamilton, Georgia  
(706) 628-5992

### Please RSVP to

Wes Swift at (404) 375-8470 or via e-mail at [wes.swift@gilead.com](mailto:wes.swift@gilead.com)  
Rhonda DeZort at (478) 320-8265 or via e-mail at [rhonda.dezort@gilead.com](mailto:rhonda.dezort@gilead.com)  
by 3/18/2019

To learn more about BIKTARVY, please [click here](#) to see the full Prescribing Information, including BOXED WARNING.

Please be aware that if you are a licensed US physician, nurse practitioner, or physician's assistant, the meal associated with this program may be reportable under the federal Open Payments/Sunshine Act and/or state law equivalents, and disclosed as required by law.

BIKTARVY, the BIKTARVY Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies.  
© 2019 Gilead Sciences, Inc. All rights reserved. BVYP0241 1/19

Sponsored by:  
 **GILEAD**